Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease
Year: 2023
Type: article
Study design: Observational Study
Abstract: Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau) 181+231 . Methods Plasma samples were analyzed using Simoa platform for 567 participants spanning the AD continuum. Cognitive diagnosis, neuropsychological testing, and dementia severity were examined for cross‐sectional and longitudinal outcomes. Results Plasma GFAP discriminated AD dementia from normal cognition (adjusted mean difference = 0.90 standard deviation [SD]) and mild cognitive impairment (adjusted mean difference = 0.72 SD), and demonstrated superior discrimination compared to alternative plasma biomarkers. Higher GFAP was associated with worse dementia severity and worse performance on 11 of 12 neuropsychological tests. Longitudinally, GFAP predicted decline in memory, but did not predict conversion to mild cognitive impairment or dementia. Discussion Plasma GFAP was associated with clinical outcomes related to suspected AD and could be of assistance in a plasma biomarker panel to detect in vivo AD.
DOI: 10.1002/dad2.12492
Authors: Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco
Institutions: Boston University, University of Arizona, Medical University of South Carolina, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, University of Gothenburg, King's College London, South London and Maudsley NHS Foundation Trust, Stavanger University Hospital, University of Pittsburgh, VA Boston Healthcare System, Framingham Heart Study, Edith Nourse Rogers Memorial Veterans Hospital, United States Department of Veterans Affairs, VA New England Healthcare System
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,310
Funders: U.S. Department of Veterans Affairs, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, European Commission, Hjärnfonden, Vetenskapsrådet, National Institutes of Health, Clinical and Translational Science Institute, Boston University, HORIZON EUROPE Framework Programme, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences
Awards: G1057200632, G1088883541, G150733400, G1551449788, G1588116593, G1802301745, G1833008592, G201353144, G2057385626, G237833635, G2510735706, G253265979, G292763017, G3133382241, G3241251457, G3470151878, G3903502641, G3914690605, G4234328627, G4260843567, G432431387, G434337789, G477853788, G5040492720, G506008078, G516766298, G5616488268, G581591135, G6158734006, G6289970089, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G6726222290, G6745400708, G6864211635, G691317373, G712881263, What determines amyloid beta aggregation and toxicity in Alzheimer’s disease?, Boston University Alzheimer's Disease Research Center, Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in blood
OpenAlex ID: W4387965067